Can pregabalin cause fatty liver? This is a common concern for patients prescribed this medication for neuropathic pain, anxiety, or epilepsy. Pregabalin, marketed as Lyrica and available generically in the UK, is not recognised as a cause of hepatic steatosis (fatty liver disease) in clinical evidence or regulatory data. The drug undergoes minimal liver metabolism and is eliminated primarily through the kidneys. However, patients taking pregabalin may experience weight gain and have underlying metabolic conditions that independently increase the risk of fatty liver. Understanding the distinction between direct drug effects and associated risk factors is essential for informed medication use.

What Is Pregabalin and How Does It Work?

Pregabalin is a prescription medicine licensed in the UK for the treatment of neuropathic pain, generalised anxiety disorder, and as an adjunctive therapy for partial seizures with or without secondary generalisation in adults. It belongs to a class of medications known as gabapentinoids and is marketed under the brand name Lyrica, though generic versions are widely available.

The drug works by binding to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system. This action reduces the release of several neurotransmitters, including glutamate, noradrenaline, and substance P, which are involved in pain signalling and neuronal excitability. By modulating these pathways, pregabalin helps to dampen abnormal electrical activity in the brain and reduce the transmission of pain signals from damaged nerves.

Pregabalin is absorbed relatively quickly from the gastrointestinal tract, with peak plasma concentrations typically reached within one hour of oral administration when taken on an empty stomach. Food delays absorption and lowers peak concentrations slightly, but this does not affect the overall clinical effect. The medication does not bind significantly to plasma proteins and is eliminated primarily unchanged through the kidneys, with minimal hepatic metabolism. This pharmacokinetic profile means that pregabalin does not undergo extensive processing by the liver, which is an important consideration when evaluating its potential effects on hepatic function.

The typical starting dose for neuropathic pain is 150 mg daily, divided into two or three doses, which may be increased to a maximum of 600 mg daily depending on individual response and tolerability. For anxiety disorders, the usual dose range is 150–600 mg daily. Dose adjustments are necessary in patients with impaired renal function, as the kidneys are the primary route of elimination. Further information on dosing, indications, and pharmacokinetics can be found in the MHRA-approved Summary of Product Characteristics (SmPC) for Lyrica and on the NHS medicines page for pregabalin.

Recognised Side Effects of Pregabalin on the Liver

When considering whether pregabalin can cause fatty liver disease (hepatic steatosis), it is important to examine the available clinical evidence and regulatory data. There is no established or officially recognised link between pregabalin use and the development of fatty liver disease. The Summary of Product Characteristics (SmPC) approved by the MHRA does not list hepatic steatosis or fatty liver as a known adverse effect of pregabalin.

The most commonly reported side effects of pregabalin affect the nervous system and include dizziness, somnolence, headache, and peripheral oedema. Gastrointestinal effects such as dry mouth, constipation, and increased appetite are also frequently observed. Weight gain (reported as 'weight increased') is a common adverse effect that occurs in a significant proportion of patients, particularly with longer-term use and higher doses. This weight gain may be clinically significant in some individuals and could theoretically contribute to metabolic changes, though this does not constitute direct hepatotoxicity.

Hepatobiliary disorders have been reported uncommonly or rarely in post-marketing surveillance. These include isolated cases of elevated liver enzymes and, very rarely, clinically apparent drug-induced liver injury such as hepatitis or cholestatic patterns. When liver enzyme elevations do occur, they are generally mild, transient, and resolve either spontaneously or upon discontinuation of the medication. Importantly, hepatic steatosis (fatty liver) is not recognised as an adverse effect of pregabalin in the UK SmPC or in post-marketing data.

It is worth noting that pregabalin's minimal hepatic metabolism means it has a low potential for causing drug-induced liver injury compared to medications that undergo extensive hepatic biotransformation. The drug does not typically require routine liver function monitoring in clinical practice, unlike many other centrally acting medications. However, any unexplained symptoms suggestive of liver dysfunction should prompt appropriate clinical investigation, regardless of the medication involved. Patients who suspect an adverse reaction to pregabalin should report it via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

Risk Factors for Liver Problems While Taking Pregabalin

Although pregabalin itself is not recognised as a cause of fatty liver disease, patients taking this medication may have other risk factors that predispose them to hepatic steatosis. Understanding these factors is essential for comprehensive patient care and appropriate clinical monitoring.

Pre-existing metabolic conditions represent significant risk factors for fatty liver disease. Type 2 diabetes mellitus, obesity (particularly central adiposity), dyslipidaemia, and metabolic syndrome are all strongly associated with non-alcoholic fatty liver disease (NAFLD), now also termed metabolic dysfunction-associated steatotic liver disease (MASLD). Many patients prescribed pregabalin for neuropathic pain secondary to diabetes may already have underlying metabolic dysfunction that increases their risk of hepatic steatosis independently of their medication.

Pregabalin-associated weight gain is a relevant consideration, as this can exacerbate existing metabolic risk factors or contribute to the development of new ones. The SmPC lists 'weight increased' as a common adverse effect. This weight gain, combined with reduced physical activity due to the underlying pain condition or sedative effects of the medication, may contribute to metabolic deterioration over time and increase the risk of developing or worsening fatty liver disease.

Polypharmacy is another important factor, as many patients taking pregabalin are also prescribed other medications that may affect liver function or metabolism. Concurrent use of other centrally acting drugs, antidepressants, or medications for metabolic conditions should be considered when evaluating overall hepatic risk. Additionally, alcohol consumption remains a major risk factor for liver disease, and patients should be counselled about safe drinking limits. The UK Chief Medical Officers advise that to keep health risks from alcohol low, it is safest not to drink more than 14 units per week on a regular basis, and to spread drinking over three or more days if you do drink as much as 14 units per week. This is particularly important as pregabalin can potentiate the sedative effects of alcohol.

Patients with chronic pain conditions may have reduced mobility and physical activity levels, which independently increase the risk of metabolic syndrome and fatty liver disease. This lifestyle factor, rather than the medication itself, may be a more significant contributor to hepatic health concerns. NICE guideline NG49 on non-alcoholic fatty liver disease provides comprehensive advice on assessment and management of patients with metabolic risk factors for liver disease.

When to Seek Medical Advice About Liver Health

Patients taking pregabalin should be aware of symptoms that may indicate liver problems and understand when to contact their GP or healthcare provider. Although serious liver complications are not typically associated with pregabalin, vigilance is appropriate for overall health monitoring.

Key symptoms warranting medical attention include:

• Jaundice – yellowing of the skin or whites of the eyes (seek urgent medical advice, especially if accompanied by fever, confusion, or severe abdominal pain)

• Persistent abdominal pain, particularly in the upper right quadrant

• Unexplained nausea, vomiting, or loss of appetite lasting more than a few days

• Dark urine or pale-coloured stools

• Unusual fatigue or weakness that is new or worsening

• Unexplained bruising or bleeding

• Itching (pruritus) without an obvious skin cause

Patients experiencing significant weight gain whilst taking pregabalin should discuss this with their healthcare provider, as it may warrant metabolic screening including liver function tests, lipid profile, and glucose monitoring. NICE guideline NG49 on non-alcoholic fatty liver disease recommends that patients with metabolic risk factors undergo appropriate assessment. In primary care, this may include non-invasive fibrosis risk scores such as the FIB-4 or NAFLD Fibrosis Score, and in some cases the Enhanced Liver Fibrosis (ELF) blood test, to identify those who may need specialist referral. The British Society of Gastroenterology (BSG) 2017 guidelines on abnormal liver blood tests provide a practical algorithm for evaluating liver function and fibrosis risk in primary care.

If you have pre-existing liver disease or risk factors for liver problems, inform your prescriber before starting pregabalin. Whilst dose adjustment is not typically required for hepatic impairment (unlike renal impairment), your doctor may wish to establish baseline liver function and monitor this periodically.

Routine monitoring of liver function is not standard practice for patients on pregabalin alone. However, if you develop new symptoms or have concerns about your liver health, your GP can arrange appropriate blood tests (liver function tests including ALT, AST, ALP, bilirubin, and albumin) to assess hepatic function. Do not stop taking pregabalin abruptly without medical advice, as this can lead to withdrawal symptoms including insomnia, headache, nausea, anxiety, sweating, and diarrhoea; any medication changes should be discussed with your healthcare provider first and dose reduction should be gradual as advised in the SmPC.

Frequently Asked Questions